Emeryville, California, United States
Contact Info
789 followers
500+ connections
About
Articles by Peter
-
Can microbes incline people to religion? My critical comment on the hypothesis
Can microbes incline people to religion? My critical comment on the hypothesis
By Peter Starokadomskyy
Activity
-
Today is National Intern Day! At Kyverna Therapeutics, we are thrilled to celebrate our four amazing 2024 summer interns. Throughout their…
Today is National Intern Day! At Kyverna Therapeutics, we are thrilled to celebrate our four amazing 2024 summer interns. Throughout their…
Liked by Peter Starokadomskyy
-
Cell therapy has evolved, Artiva Bio lands $167m IPO, Investors are focusing beyond oncology 👇 CAR-T therapy, 𝘪𝘯𝘪𝘵𝘪𝘢𝘭𝘭𝘺…
Cell therapy has evolved, Artiva Bio lands $167m IPO, Investors are focusing beyond oncology 👇 CAR-T therapy, 𝘪𝘯𝘪𝘵𝘪𝘢𝘭𝘭𝘺…
Liked by Peter Starokadomskyy
-
$1.05B acquisition of ATEM Capital portfolio company Amolyt Pharma by AstraZeneca is now officially closed. Congratulations to everyone involved in…
$1.05B acquisition of ATEM Capital portfolio company Amolyt Pharma by AstraZeneca is now officially closed. Congratulations to everyone involved in…
Liked by Peter Starokadomskyy
Experience & Education
Publications
-
Innate immunity as the first responder
Frontiers Cell.Infect.Microbiol
Innate immunity and interferon signaling are versatile tools, developed by cells early in Evolution. Its wide number of cross-connection with the entire metabolism of cells and tissues make it the universal first responder to any problem the cell faces: from infection to abnormal host metabolism.
-
NK cell defects in X-linked pigmentary reticulate disorder
JCI Insight
X-linked reticulate pigmentary disorder (XLPDR, Mendelian Inheritance in Man #301220) is a rare syndrome characterized by recurrent infections and sterile multiorgan inflammation. The syndrome is caused by an intronic mutation in POLA1, the gene encoding the catalytic subunit of DNA polymerase-α (Pol-α), which is responsible for Okazaki fragment synthesis during DNA replication. Reduced POLA1 expression in this condition triggers spontaneous type I interferon expression, which can be linked to…
X-linked reticulate pigmentary disorder (XLPDR, Mendelian Inheritance in Man #301220) is a rare syndrome characterized by recurrent infections and sterile multiorgan inflammation. The syndrome is caused by an intronic mutation in POLA1, the gene encoding the catalytic subunit of DNA polymerase-α (Pol-α), which is responsible for Okazaki fragment synthesis during DNA replication. Reduced POLA1 expression in this condition triggers spontaneous type I interferon expression, which can be linked to the autoinflammatory manifestations of the disease. However, the history of recurrent infections in this syndrome is as yet unexplained. Here we report that patients with XLPDR have reduced NK cell cytotoxic activity and decreased numbers of NK cells, particularly differentiated, stage V, cells (CD3-CD56dim). This phenotype is reminiscent of hypomorphic mutations in MCM4, which encodes a component of the minichromosome maintenance (MCM) helicase complex that is functionally linked to Pol-α during the DNA replication process. We find that POLA1 deficiency leads to MCM4 depletion and that both can impair NK cell natural cytotoxicity and show that this is due to a defect in lytic granule polarization. Altogether, our study provides mechanistic connections between Pol-α and the MCM complex and demonstrates their relevance in NK cell function.
-
DNA polymerase-α regulates the activation of type I interferons through cytosolic RNA:DNA synthesis
Nature Immunology
We discovered that XLPDR is caused by an intronic mutation that disrupts the expression of POLA1, which encodes the catalytic subunit of DNA polymerase-α. Unexpectedly, POLA1 deficiency resulted in increased production of type I interferons. This enzyme is necessary for the synthesis of RNA:DNA primers during DNA replication and, strikingly, we found that POLA1 is also required for the synthesis of cytosolic RNA:DNA, which directly modulates interferon activation. Together this work identifies…
We discovered that XLPDR is caused by an intronic mutation that disrupts the expression of POLA1, which encodes the catalytic subunit of DNA polymerase-α. Unexpectedly, POLA1 deficiency resulted in increased production of type I interferons. This enzyme is necessary for the synthesis of RNA:DNA primers during DNA replication and, strikingly, we found that POLA1 is also required for the synthesis of cytosolic RNA:DNA, which directly modulates interferon activation. Together this work identifies POLA1 as a critical regulator of the type I interferon response.
Other authorsSee publication -
Microbes on the edge of Occam’s razor
Biology Direct
Our body harbors hundreds of microbial species and contains many more bacterial than human cells. These microbes are not passive riders but rather a vital component of the organism. The human microbiota affects our health in multiple ways, both positively and negatively. One of the new attractive directions in microbiome biology is the “microbiome-brain axis”. Several groups of researchers have described the ability of the gut microbiota to communicate with the brain and thus modulate human…
Our body harbors hundreds of microbial species and contains many more bacterial than human cells. These microbes are not passive riders but rather a vital component of the organism. The human microbiota affects our health in multiple ways, both positively and negatively. One of the new attractive directions in microbiome biology is the “microbiome-brain axis”. Several groups of researchers have described the ability of the gut microbiota to communicate with the brain and thus modulate human behavior. These limited experimental data became the foundation of the “biomeme hypothesis” of possible microbial origin of some religious rituals that has recently appeared in Biology Direct. Here I propose a critical analysis of this hypothesis. I conclude that there is no evidence of the microbial origin of religious practices but there are strong indications of their psychological and social roots.
-
Copper Metabolism Domain-containing 1 Represses Genes that Promote Inflammation and Protects Mice From Colitis and Colitis-associated Cancer
Gastroenterology
In comparing gene expression patterns between myeloid cells from Mye-K/O and wild-type mice, we found that COMMD1 represses expression of genes induced by LPS. Mye-K/O mice had more intense inflammatory responses to LPS and developed more severe sepsis and colitis, with greater mortality. More Mye-K/O mice with colitis developed colon dysplasia and tumors than wild-type mice. We observed a reduced expression of COMMD1 in colon biopsy specimens and circulating leukocytes from patients with IBD…
In comparing gene expression patterns between myeloid cells from Mye-K/O and wild-type mice, we found that COMMD1 represses expression of genes induced by LPS. Mye-K/O mice had more intense inflammatory responses to LPS and developed more severe sepsis and colitis, with greater mortality. More Mye-K/O mice with colitis developed colon dysplasia and tumors than wild-type mice. We observed a reduced expression of COMMD1 in colon biopsy specimens and circulating leukocytes from patients with IBD. We associated single-nucleotide variants near COMMD1 with reduced expression of the gene and linked them with increased risk for ulcerative colitis.
-
A bird's-eye view of autophagy
Autophagy
Autophagy is a process in which a eukaryotic (but not prokaryotic) cell destroys its own components through the lysosomal machinery. This tightly regulated process is essential for normal cell growth, development, and homeostasis, serving to maintain a balance between synthesis and degradation, resulting in the recycling of cellular products. Here we try to expand the concept of autophagy and define it as a general mechanism of regulation encompassing various levels of the biosphere…
Autophagy is a process in which a eukaryotic (but not prokaryotic) cell destroys its own components through the lysosomal machinery. This tightly regulated process is essential for normal cell growth, development, and homeostasis, serving to maintain a balance between synthesis and degradation, resulting in the recycling of cellular products. Here we try to expand the concept of autophagy and define it as a general mechanism of regulation encompassing various levels of the biosphere. Interestingly, one of the consequences of such an approach is that we must presume an existence of the autophagic processes in the prokaryotic domain.
Patents
-
Ultrasound assisted immunoassay
Filed US 13386881
How to develop Western Blotting images cleaner and quicker
Honors & Awards
-
First prize award
Institute of Molecular biology and Genetics of NAS of Ukraine
The laureate of grant from Institute of Molecular biology and Genetics of NAS of Ukraine for the best scientific publication of in field of biotechnology
-
Second place award
Conference “Actual problems of biochemistry and biotechnology”, Kiev, Ukraine
Presentation “Optimization of recombinant protein obtaining and purification using protein splicing”.
-
Yearly National Scholarship Award
Worldwide Federation of Scientist (Lausanne, Switzerland)
Yearly National Scholarship Award from Worldwide Federation of Scientist (Lausanne, Switzerland) for a project, dedicated to studying of physiological features of a lysalbilic acid, a new absorption promoter for the buccal delivery.
Languages
-
English
Native or bilingual proficiency
-
French
Professional working proficiency
-
Ukrainian
Native or bilingual proficiency
More activity by Peter
-
Cell Therapy IPO Raises $167M, Autoimmunity Research Strengthens 👇 Artiva Biotherapeutics today raised a better than predicted $167 million in an…
Cell Therapy IPO Raises $167M, Autoimmunity Research Strengthens 👇 Artiva Biotherapeutics today raised a better than predicted $167 million in an…
Liked by Peter Starokadomskyy
-
Friday will be (another) public litmus test for autoimmune-targeting cell therapies - or at least one company's approach towards them. After getting…
Friday will be (another) public litmus test for autoimmune-targeting cell therapies - or at least one company's approach towards them. After getting…
Liked by Peter Starokadomskyy
-
𝐓𝐂𝐑 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 🧪 With 30+ companies and 50+ programs including multiple Phase 2 pipelines - the primary aim of TCR…
𝐓𝐂𝐑 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 🧪 With 30+ companies and 50+ programs including multiple Phase 2 pipelines - the primary aim of TCR…
Liked by Peter Starokadomskyy
-
If you have a background in any of those, #neuroscience #optics #multiphoton #microscopy like the idea of building prototypes that you designed with…
If you have a background in any of those, #neuroscience #optics #multiphoton #microscopy like the idea of building prototypes that you designed with…
Liked by Peter Starokadomskyy
-
Kyverna Therapeutics wins RMAT designation for stiff-person syndrome for cell therapy candidate Kyverna’s CEO Peter Maag said the biotech is “eager…
Kyverna Therapeutics wins RMAT designation for stiff-person syndrome for cell therapy candidate Kyverna’s CEO Peter Maag said the biotech is “eager…
Liked by Peter Starokadomskyy
-
As Chief Medical Officer, James Chung is spearheading clinical trials to test CAR T cells in patients with multiple sclerosis. Speaking with Drug…
As Chief Medical Officer, James Chung is spearheading clinical trials to test CAR T cells in patients with multiple sclerosis. Speaking with Drug…
Liked by Peter Starokadomskyy
-
CAR-Ts sweep into autoimmunity Good article in Nature Biotechnology providing an overview of the biotech landscape focusing on CAR-T cells to target…
CAR-Ts sweep into autoimmunity Good article in Nature Biotechnology providing an overview of the biotech landscape focusing on CAR-T cells to target…
Liked by Peter Starokadomskyy
-
Excitement for CAR T cell therapy in Autoimmune is building. Trailblazing in this paradigm shift with the team at Kyverna to the benefit of patients…
Excitement for CAR T cell therapy in Autoimmune is building. Trailblazing in this paradigm shift with the team at Kyverna to the benefit of patients…
Liked by Peter Starokadomskyy
-
𝐓 𝐂𝐞𝐥𝐥 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 🔬 The T cell autoimmune pipelines feature prominent players, showcasing a robust presence…
𝐓 𝐂𝐞𝐥𝐥 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 🔬 The T cell autoimmune pipelines feature prominent players, showcasing a robust presence…
Liked by Peter Starokadomskyy
-
Following the FDA granting Kyverna a Regenerative Medicine Advanced Therapy designation for patients with refractory Stiff-Person Syndrome, our CEO…
Following the FDA granting Kyverna a Regenerative Medicine Advanced Therapy designation for patients with refractory Stiff-Person Syndrome, our CEO…
Liked by Peter Starokadomskyy
-
ADCs are hot right now, but amongst big pharma, not everyone has jumped in with the same enthusiasm I took a look at the oncology portfolios of the…
ADCs are hot right now, but amongst big pharma, not everyone has jumped in with the same enthusiasm I took a look at the oncology portfolios of the…
Liked by Peter Starokadomskyy
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More